Questions: Renal Osteodystrophy and Mineral Metabolism

Question 1

In early CKD (GFR ~60 mL/min), serum phosphate is often near-normal despite reduced renal excretion capacity. What primarily compensates for the phosphate retention?

• A. Patients spontaneously restrict dietary phosphate intake at this stage
• B. Elevated FGF23 increases urinary phosphate excretion to compensate for reduced GFR
• C. PTH directly suppresses intestinal phosphate absorption
• D. Calcitriol stimulates renal tubular phosphate reabsorption, redistributing phosphate to bone

Answer: (B)

FGF23 is the primary early compensatory mechanism. As phosphate begins to accumulate with falling GFR, bone cells release FGF23, which signals the kidney to increase phosphate excretion — keeping serum phosphate near normal at the expense of dramatically elevated FGF23 levels. This is why serum phosphate is an insensitive early biomarker of CKD-MBD; normal phosphate does not mean normal mineral metabolism. FGF23 also suppresses calcitriol synthesis as a side effect, beginning the downstream cascade. Option C has PTH's phosphate effects reversed: PTH is phosphaturic (reduces reabsorption), but it is not primarily driven by phosphate at this stage.

Question 2

A CKD patient treated aggressively with calcium-based phosphate binders develops suppressed PTH levels (adynamic bone disease). What is the primary risk of this state?

• A. Rebound PTH elevation will cause high-turnover bone disease once binders are stopped
• B. Normalized bone turnover reduces the risk of fractures as osteoclast activity is quieted
• C. Bone cannot remodel normally, reducing its ability to repair microfractures from daily stress
• D. Vascular calcification is prevented because calcium is bound in the gut rather than deposited in vessels

Answer: (C)

Adynamic bone disease occurs when PTH is over-suppressed, causing both osteoblast and osteoclast activity to fall below physiologically normal levels. Bone loses its capacity for remodeling — the continuous process of repairing microfractures and replacing old matrix. The result is paradoxically fragile bone that accumulates damage. This is why therapeutic management aims to keep turnover in a normal physiological range, not to minimize PTH completely. Option D is incorrect: calcium-based binders can actually worsen vascular calcification by increasing the calcium load absorbed from the gut.

Question 3

Vascular calcification in CKD is a passive process caused by calcium-phosphate precipitating in damaged arterial walls.

• T. True
• F. False

Answer: False

This is explicitly a misconception stated in the topic. Vascular calcification in CKD is an active, cell-mediated process: high phosphate levels drive vascular smooth muscle cells to transdifferentiate into an osteoblast-like phenotype, actively synthesizing hydroxyapatite within the arterial media. The inhibitory proteins fetuin-A and matrix Gla protein normally prevent this; CKD overwhelms these systems. Understanding this as active osteogenesis rather than passive precipitation matters clinically — it identifies cellular targets (the transdifferentiation pathway, Gla protein activation) that mere calcium-lowering cannot address.

Question 4

In advanced CKD, serum phosphate can rise overtly despite maximally elevated FGF23 because the kidney loses its ability to respond to FGF23's phosphaturic signal.

• T. True
• F. False

Answer: True

In early CKD, FGF23 compensates effectively — its dramatic rise keeps phosphate near normal. But as nephron mass falls, the kidney has fewer functional tubular cells to execute FGF23's phosphaturic signal. The remaining nephrons cannot compensate, and phosphate rises overtly despite extremely high FGF23 levels. This dissociation between FGF23 and phosphate is one reason why serum phosphate becomes difficult to control in advanced CKD and why phosphate binders become essential. It also illustrates why FGF23 itself is now considered a cardiovascular risk factor independent of phosphate.

Question 5

Why does simply taking calcium supplements fail to address bone disease in advanced CKD, even though low calcium is part of the underlying problem?

Model answer: In advanced CKD, the bone disease arises from multiple simultaneous disruptions: the kidney cannot synthesize calcitriol, so intestinal calcium absorption is impaired regardless of dietary calcium; phosphate retention creates a high calcium-phosphate product that can promote ectopic calcification while simultaneously suppressing active vitamin D synthesis; and secondary hyperparathyroidism drives high-turnover bone disease through osteoclast activation. Calcium supplements address only one node — they may raise serum calcium briefly, but without calcitriol they cannot improve absorption, and excessive calcium can worsen vascular calcification. The underlying derangements (phosphate retention, calcitriol deficiency, PTH excess) each require targeted intervention.

The lesson is that CKD-MBD is not a single-deficiency disease but a multi-node disruption of the calcium-phosphate-PTH-vitamin D axis. Treatment requires coordinated management: phosphate binders to reduce the primary stimulus, supplemental calcitriol or analogs, and calcimimetics to suppress PTH — often all simultaneously.